Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application. The listing is based on the PCT amended claims submitted with the original U.S. application.

Listing of Claims:

Claim 1 (currently amended): ~~Method~~ A method for targeting cells involved in sclerotic and/or fibrotic diseases, and in which cells the PDGF-receptor is upregulated during disease, in a tissue sample of a subject using a carrier molecule, said carrier molecule being linked to at least one further molecule, said further molecule ~~being selected from the group consisting of:~~

~~- a cyclic peptide comprising the amino acid sequence RGD~~

~~- a cyclic peptide comprising the amino acid sequence KPT~~

~~- a cyclic peptide comprising the amino acid sequence RKKP~~

comprising a cyclic peptide comprising the amino acid sequence SRNLIDC~~;~~ ~~and~~

~~a molecule capable of recognising and binding mannose-6-phosphate receptor and at least an amount that is equivalent to at least 10 molecules capable of recognising and capable of binding mannose-6-phosphate receptor linked to HSA are linked to the carrier molecule~~.

Claim 2 (currently amended): ~~Method~~ A method for targeting cells involved in sclerotic and/or fibrotic diseases, and in which cells the PDGF-receptor is upregulated during disease, in a subject using, in a pharmaceutically acceptable amount and form a carrier molecule, said carrier molecule being linked to at least one further molecule, said further molecule ~~being selected from the group consisting of:~~

~~- a cyclic peptide comprising the amino acid sequence RGD~~

~~- a cyclic peptide comprising the amino acid sequence KPT~~

~~- a cyclic peptide comprising the amino acid sequence RKKP~~

comprising[[-]] a cyclic peptide comprising the amino acid sequence SRNLIDC ~~a~~

~~molecule capable of recognising and binding mannose-6-phosphate receptor and at least an amount that is equivalent to at least 10 molecules capable of recognising and capable of binding mannose-6-phosphate receptor linked to HSA are linked to the carrier molecule~~.

Claim 3 (currently amended): ~~Method~~ A method according to claim 1 or 2, wherein the cells ~~comprise at least one target receptor specific for~~ are Hepatic Stellate Cells (HSC) ~~or a receptor that is upregulated on HSC during disease~~.

Claim 4 (canceled).

Claim 5 (currently amended): ~~Method~~ A method according to claim 1 or 2, ~~any of the preceding claims,~~ wherein the carrier molecule comprises additional drugs or chemicals linked thereto.

Claim 6 (currently amended): ~~Method~~ A method according to claim 1 or 2, ~~any of the preceding claims,~~ wherein the carrier molecule comprises a diagnostic marker attached thereto.

Claim 7 (currently amended): ~~Method~~ A method according to claim 1 or 2, ~~any of the preceding claims~~ wherein the cells involved in a sclerotic and/or a fibrotic disease are cells involved in a disease selected from the group consisting of liver fibrosis, ~~in particular cirrhosis,~~ kidney fibrosis, ~~in particular glomerulosclerosis and interstitial fibrosis,~~ lung fibrosis, atherosclerosis and chronic or acute inflammatory processes ~~such as rheumatoid arthritis~~, Crohns disease, colitis ulcerosa, glomerulonephritis, sepsis and tumor-cell proliferation associated pathology, fibroblast proliferation associated pathology, endothelial cell proliferation associated pathology and osteoblast proliferation associated pathology.

Claim 8 (canceled).

Claim 9 (canceled).

Claim 10 (cancelled).

Claim 11 (canceled).

Claim 12 (canceled).

Claim 13 (canceled).

Claim 14 (currently amended): ~~Compound~~ A compound for targeting cells involved in sclerotic and/or fibrotic diseases, and in which cells the PDGF-receptor is upregulated during disease, wherein said compound comprises ~~being~~ a carrier molecule linked to at least one further molecule said further molecule being X*SRNLIDCX*, wherein X* represents the location of cyclisation.

Claim 15 (canceled).

Claim 16 (currently amended): ~~Compound~~ A compound according to ~~any of claims 10-15~~ claim 14, wherein X* is a cystein residue.

Claim 17 (currently amended): ~~Compound~~ A compound according to any ~~of claims 10-16~~ claim 14, wherein X* represents the location of cyclisation and attachment to the carrier molecule.

Claim 18 (currently amended): ~~Compound~~ A compound according to ~~any of the claims 8-17~~ claim 14, wherein of the further molecule the cyclic portion of the cyclic peptide comprises multiple receptor binding sequences.

Claim 19 (currently amended): ~~Compound~~ A compound according to ~~any of the claims 10-18~~ claim 14, wherein of the further molecule the cyclic portion of the

cyclic peptide comprises multiple receptor binding sequences directed at at least two different types of receptors.

Claim 20 (currently amended): ~~Compound~~ A compound according to ~~any of the claims 10-19~~ claim 14, wherein the further molecule comprises multiple cyclic peptides directed at the same or different types of receptors.

Claim 21 (currently amended): ~~Compound~~ A compound according to ~~any of the claims 8-20~~ claim 14 , wherein the carrier molecule is selected from the group of carrier molecules consisting of proteins, oligo or polypeptides, immunoglobulins or parts thereof, oligonucleotides, disaccharides, polysaccharides, biodegradable synthetic polymers, liposomes, lipid particles, biocompatible polymers in the form of microspheres or nanoparticles, endogenous plasma proteins, ~~e.g. albumin,~~ lactoferrin, alkaline phosphatase, superoxide dismutase, alpha2 macroglobulin and fibronectin.

Claim 22 (currently amended): ~~Compound~~ A compound according to ~~any of the claims 8-21~~ claim 14, wherein the carrier molecule comprises additional drugs or chemicals linked thereto.

Claim 23 (currently amended): ~~Compound~~ A compound according to ~~any of the claims 8-23~~ claim 14, wherein the carrier molecule comprises a diagnostic marker attached thereto.

Claim 24 (currently amended): ~~Pharmaceutical~~ A pharmaceutical composition comprising a compound according to any one of claims ~~8-23~~ 14 or 16-23 as targeting ingredient and one or more pharmaceutically acceptable carriers.

Claim 25 (currently amended): A method of using ~~Use of~~ a compound according to any one of claims 14 or 16-23 ~~claim 8-23~~ for in vitro diagnosis of a sclerotic and/or fibrotic disease ~~in particular for in vitro diagnosis of a disease~~ selected from the group consisting of liver fibrosis, ~~in particular cirrhosis,~~ kidney fibrosis, ~~in~~

~~particular glomerulosclerosis and interstitial fibrosis~~, lung fibrosis, atherosclerosis and chronic or acute inflammatory processes ~~such as rheumatoid arthritis~~, Crohns disease, colitis ulcerosa, glomerulonephritis, sepsis and tumor-cell proliferation associated pathology, fibroblast proliferation associated pathology, endothelial cell proliferation associated pathology and osteoblast proliferation associated pathology.

Claim 26 (currently amended): A method of using ~~Use of~~ a compound according to any one of claims 14 or 16-23 ~~claim 8-23~~ for the preparation of a medicament for *in vivo* diagnosis, prophylaxis and/or therapy of a sclerotic and/or fibrotic disease ~~in particular for in vitro diagnosis of a disease~~ selected from the group consisting of liver fibrosis, ~~in particular cirrhosis,~~ kidney fibrosis, ~~in particular glomerulosclerosis and interstitial fibrosis,~~ lung fibrosis, atherosclerosis and chronic or acute inflammatory processes ~~such as rheumatoid arthritis~~, Crohns disease, colitis ulcerosa, glomerulonephritis, sepsis and tumor-cell proliferation associated pathology, fibroblast proliferation associated pathology, endothelial cell proliferation associated pathology and osteoblast proliferation associated pathology.

27. (New) Method according to claim 7, wherein said liver fibrosis is liver cirrhosis and said kidney fibrosis is glomerulosclerosis or interstitial fibrosis.

28. (New) Method according to claim 21, wherein said endogenous plasma protein is albumin.

29. (New) Method according to claim 25, wherein said liver fibrosis is cirrhosis, said kidney fibrosis is glomerulosclerosis or interstitial fibrosis, and said chronic or acute inflammatory process is rheumatoid arthritis.

30. (New) Method according to claim 26, wherein said liver fibrosis is cirrhosis, said kidney fibrosis is glomerulosclerosis or interstitial fibrosis, said chronic or acute inflammatory process is rheumatoid arthritis.